相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Liposomal drug delivery systems: From concept to clinical applications
Theresa M. Allen et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
A. C. Roy et al.
ANNALS OF ONCOLOGY (2013)
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
A. H. Ko et al.
BRITISH JOURNAL OF CANCER (2013)
Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes
Shawn Stapleton et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts
Pin-Yuan Chen et al.
NEURO-ONCOLOGY (2013)
The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
Jean-Marie Gibson et al.
ONCOLOGIST (2013)
Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model
M. Verreault et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine
Maite Verreault et al.
BMC CANCER (2011)
Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo Laboratory investigation
Weijun Wang et al.
JOURNAL OF NEUROSURGERY (2011)
Drug Targeting to Monocytes and Macrophages Using Esterase-Sensitive Chemical Motifs
Lindsey A. Needham et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Vincristine Sulfate Liposomes Injection (Marqibo) in Heavily Pretreated Patients With Refractory Aggressive Non-Hodgkin Lymphoma Report of the Pivotal Phase 2 Study
M. A. Rodriguez et al.
CANCER (2009)
Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine
Charles O. Noble et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Improved Pharmacokinetics and Efficacy of a Highly Stable Nanoliposomal Vinorelbine
Daryl C. Drummond et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts
Michal T. Krauze et al.
NEURO-ONCOLOGY (2007)
Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice
Bhawna Gupta et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
DC Drummond et al.
CANCER RESEARCH (2006)
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: Pharmacology and efficacy
CO Noble et al.
CANCER RESEARCH (2006)
Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma - A phase III multicenter randomized trial
RM Rifkin et al.
CANCER (2006)
Barriers to carrier mediated drug and gene delivery to brain tumors
GH Huynh et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-Lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis
DF Nellis et al.
BIOTECHNOLOGY PROGRESS (2005)
Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification
DF Nellis et al.
BIOTECHNOLOGY PROGRESS (2005)
Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo
C Mamot et al.
CANCER RESEARCH (2005)
Effect of repetitive administration of doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model
RD Arnold et al.
CLINICAL CANCER RESEARCH (2005)
Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain
R Saito et al.
EXPERIMENTAL NEUROLOGY (2005)
Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients
E Cecchin et al.
CLINICAL CANCER RESEARCH (2005)
Molecular biology of the blood-brain barrier
WM Pardridge
MOLECULAR BIOTECHNOLOGY (2005)
Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in lipsomes or ErbB2-targeted immunoliposomes
DC Drummond et al.
CLINICAL CANCER RESEARCH (2005)
Pegylated liposomal doxorubicin: Optimizing the dosing schedule in ovarian cancer
PG Rose
ONCOLOGIST (2005)
Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating
JA MacKay et al.
BRAIN RESEARCH (2005)
Role of pegylated liposomal doxorubicin in ovarian cancer
JT Thigpen et al.
GYNECOLOGIC ONCOLOGY (2005)
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study
MD Prados et al.
NEURO-ONCOLOGY (2004)
Liposomal irinotecan: Formulation development and therapeutic assessment in murine xenograft models of colorectal cancer
CL Messerer et al.
CLINICAL CANCER RESEARCH (2004)
Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma
TC Chen et al.
CANCER (2003)
Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors
A Pluen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues:: comparison with p-nitra-phenylacetate converting carboxylesterase activity
I Hennebelle et al.
ANTI-CANCER DRUGS (2000)
分享论文
